Abstract:OBJECTIVE:To determine the predictive value of excision repair cross complement-1 (ERCC-1) expression and the sensitivity of cisplatin-based chemotherapy in advance non-small cell lung cancer (NSCLC). METHODS: From February 1,2000 to June 30,2004, 51 specimens of paraffin-embedded tissues of pathologically confirmed advanced NSCLC were studied. All patients received cisplatin contained regimen chemotherapy. The expression of ERCC-1 in tumor samples was examined by the immunohistochemical supervisiontm method. The response rates and survival data were analyzed according to the over-expression or not of the parameter. RESULTS: In these 51 patients, over expression rates of ERCC-1 was 64.7%(33/51). The response rate of cisplatin-based chemotherapy in negative group and over expression group of ERCC-1 were 72.2% and 42.4% respectively,being a significant difference (χ2=4.151, P=0.042). The average survival time in negative group and over-expression group were 12.5 and 9.3 months for ERCC-1, being a significant difference ( χ2= 5.61, P=0.018). The 1-year survival time in negative group and over-expression group were 72.2% and 30.3% for ERCC-1, being a significant diference (χ2=8.267, P=0.004). CONCLUSION: ERCC-1 can be used as a molecular marker of cisplatin sensitivity and prognosis in advanced NSCLC patients.

Expression of ERCC-1 in NSCLC tissue and its value for appraising chemotherapy